AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 28512699
Drug: 60-mg edoxaban
RxNorm normalized name: edoxaban 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60-mg edoxaban tablet crushed and administered in apple puree
Trial: 28512699
Drug: 60-mg edoxaban
RxNorm normalized name: edoxaban 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60-mg edoxaban tablet (whole)
Trial: 28512699
Drug: nasogastric tube
RxNorm normalized name: nasogastric tube
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nasogastric tube suspension
Trial: 24815673
Drug: ziprasidone (40-160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ziprasidone (40-160 mg/day)
Trial: 12419717
Drug: Ondansetron 4
RxNorm normalized name: ondansetron 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron 4 mg and dexamethasone 8 mg (OD8 group)
Trial: 12419717
Drug: Ondansetron 4
RxNorm normalized name: ondansetron 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron 4 mg and dexamethasone 16 mg (OD16 group)
Trial: 12419717
Drug: Ondansetron 4
RxNorm normalized name: ondansetron 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron 4 mg (O group)
Trial: 12419717
Drug: Ondansetron 4
RxNorm normalized name: ondansetron 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron 4 mg and dexamethasone 2 mg (OD2 group)
Trial: 12419717
Drug: Ondansetron 4
RxNorm normalized name: ondansetron 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron 4 mg and dexamethasone 4 mg (OD4 group)
Trial: 1683818
Drug: E100 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E100 (100 mg esmolol)
Trial: 1683818
Drug: E200 (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E200 (200 mg esmolol)
Trial: 31288561
Drug: Insulin-dependent DM
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin-dependent DM
Trial: 25935943
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (paracetamol 500 mg + metoclopramide 10 mg + flunarizine 10 mg + alprazolam 0.5 mg)
Trial: 19079814
Drug: TJ‐54 treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TJ‐54 treatment (yokukansan) in period I
Trial: 19079814
Drug: TJ‐54 treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TJ‐54 treatment (yokukansan) in period II
Trial: 19079814
Drug: TJ‐54 treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TJ‐54 treatment in group A
Trial: 19079814
Drug: TJ‐54 treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TJ‐54 treatment in group B
Trial: 19079814
Drug: TJ‐54 treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TJ‐54 treatment
Trial: 18085465
Drug: Olopatadine 0.2%
DrugBank: Olopatadine (DB00768)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olopatadine 0.2% ophthalmic solution (Pataday)
Trial: 18085465
Drug: Olopatadine 0.1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olopatadine 0.1% ophthalmic solution (Patanol)
Trial: 16026692
Drug: Protracted venous
RxNorm normalized name: bushmaster venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protracted venous infusion (PVI) 5-FU for 12 weeks
Trial: 11920308
Drug: Oral ganciclovir
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ganciclovir for 8 weeks
Trial: 10357377
Drug: Highly aggressive
RxNorm normalized name: Recombinant human highly phosphorylated acid alpha-glucosidase
DrugBank: Recombinant human highly phosphorylated acid alpha-glucosidase (DB17673)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Highly aggressive antiretroviral therapy (HAART)
Trial: 10357377
Drug: Triple combination
RxNorm normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple combination (ZDV, 3TC, SQV)
Trial: 10357377
Drug: Quadruple combination
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadruple combination (ZDV, 3TC, SQV, RTV)
Trial: 7573097
Drug: Interferon-α (IFN-α)
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon-α (IFN-α) therapy at a dosage of 5 million units (MU)/m2 per day
Trial: 7573097
Drug: Interferon-α (IFN-α)
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon-α (IFN-α) therapy
Trial: 7573097
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Interferon-α (IFN-α) and chemotherapy
Trial: 2149493
Drug: Teicoplanin 6
RxNorm normalized name: teicoplanin 66.7 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teicoplanin 6 mg/kg
Trial: 7381125
Drug: Metaproterenol 0.65
RxNorm normalized name: metaproterenol 0.65 mg/inh inhalation aerosol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metaproterenol 0.65 mg (3 inhalations at 10 and 20 min)
Trial: 7381125
Drug: Metaproterenol 1.95
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metaproterenol 1.95 mg (single inhalation)
Trial: 21649633
Drug: All treatments
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All treatments (FL, PSI, FL+PSI)
Trial: 14555862
Drug: Rofecoxib (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rofecoxib (25 mg cumulative dose: 6.25 mg + 18.75 mg 1 h later)
Trial: 3885033
Drug: Penicillamine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Penicillamine (1 g per day)
Trial: 30221864
Drug: Magnesium oxide
RxNorm normalized name: Magnesium Oxide
DrugBank: Magnesium oxide (DB01377)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Magnesium oxide treatment
Trial: 24233343
Drug: HPV16 synthetic
RxNorm normalized name: Camphor (synthetic)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPV16 synthetic long-peptide vaccine (HPV16-SLP)
Trial: 10388649
Drug: Vaccine formulated
RxNorm normalized name: hepatitis B vaccine, unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine formulated into Iscom particles
Trial: 10388649
Drug: Standard influenza
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard influenza vaccine
Trial: 1799472
Drug: Chlorambucil (CB;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorambucil (CB; 10 mg/day)
Trial: 1799472
Drug: Maintenance therapy
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance therapy with interferon alfa‐2b
Trial: 29397092
Drug: Rhus capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rhus capsules
Trial: 27689547
Drug: Steroid +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid + antiviral
Trial: 24152667
Drug: Home-based case
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based case management intervention (monthly home visits by nurses and physiotherapists for 12 months)
Trial: 18033323
Drug: Etoposide, daunomycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoposide, daunomycin (therapy likely to generate DNA double-strand breaks)
Trial: 18033323
Drug: Anti-metabolite therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-metabolite therapy (fludarabine, cytarabine)
Trial: 7731622
Drug: Morphine sulphate
RxNorm normalized name: Morphine sulphate
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morphine sulphate (i.v.)
Trial: 6116296
Drug: Ketotifen 1
RxNorm normalized name: ketotifen 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketotifen 1 mg bd for four weeks
Trial: 6116296
Drug: Ketotifen 1
RxNorm normalized name: ketotifen 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketotifen 1 mg, 2 mg, and 4 mg before exercise
Trial: 28567691
Drug: Adipose tissue-derived
RxNorm normalized name: human adipose preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adipose tissue-derived stem cells (ASCs) at a dose of 1 × 10^7 cells/mL
Trial: 28567691
Drug: Adipose tissue-derived
RxNorm normalized name: human adipose preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adipose tissue-derived stem cells (ASCs) at a dose of 2 × 10^7 cells/mL
Trial: 26579572
Drug: Fluoxetine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (20 mg in the morning) and placebo (in the evening) for 24 weeks
Trial: 26579572
Drug: Fluoxetine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (20 mg in the morning) and melatonin (5 mg in the evening) for 24 weeks
Trial: 23713815
Drug: Rate control
RxNorm normalized name: tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rate control strategy for treatment of AF
Trial: 23713815
Drug: Rhythm control
RxNorm normalized name: ALUMINUM ZIRCONIUM TRICHLOROHYDREX GLY 180 mg in 1 g TOPICAL STICK [ZUSKA RHYTHM]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rhythm control strategy for treatment of AF
Trial: 21676011
Drug: XEN-D0501 1
RxNorm normalized name: XEN-D0501
DrugBank: XEN-D0501 (DB18673)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XEN-D0501 1 mg twice daily
Trial: 21676011
Drug: XEN-D0501 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XEN-D0501 2.5 mg twice daily
Trial: 21676011
Drug: XEN-D0501 5
RxNorm normalized name: XEN-D0501
DrugBank: XEN-D0501 (DB18673)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XEN-D0501 5 mg twice daily
Trial: 21676011
Drug: XEN-D0501 5
RxNorm normalized name: XEN-D0501
DrugBank: XEN-D0501 (DB18673)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XEN-D0501 5 mg single dose (fasted and fed conditions)
Trial: 17205438
Drug: Single-dose azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single-dose azithromycin (1 g)
Trial: 17205438
Drug: 3-day azithromycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-day azithromycin (500 mg daily)
Trial: 17205438
Drug: 3-day levofloxacin
RxNorm normalized name: Levofloxacine
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3-day levofloxacin (500 mg daily)
Trial: 17205438
Drug: Azithromycin-based regimens
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin-based regimens (single-dose and 3-day)
Trial: 15601351
Drug: 0.1% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% bupivacaine + 5 microg x ml(‐1) fentanyl
Trial: 15601351
Drug: 0.0625% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.0625% bupivacaine + 5 microg x ml(‐1) fentanyl
Trial: 9127169
Drug: Octreotide, 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide, 40 micrograms/h, by continuous i.v. infusion for 5 days
Trial: 9127169
Drug: Placebo in
RxNorm normalized name: placebo INTRAVEN VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo in addition to standard supportive therapy
Trial: 1492864
Drug: 6-mg DHEC
RxNorm normalized name: DHEC
DrugBank: Dihydroergocristine (DB13345)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-mg DHEC oral vial once daily for 3 months
Trial: 1492864
Drug: 6-mg DHEC
RxNorm normalized name: DHEC
DrugBank: Dihydroergocristine (DB13345)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-mg DHEC tablet once daily for 3 months
Trial: 1492864
Drug: Placebo vial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo vial once daily for 3 months
Trial: 1492864
Drug: Placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet once daily for 3 months
Trial: 31228760
Drug: AFS (fentanyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AFS (fentanyl bolus ± infusions)
Trial: 31228760
Drug: PDS +
RxNorm normalized name: Dianeal PD-2/2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PDS + DSI (protocol-directed sedation + daily sedation interruption)
Trial: 29197140
Drug: IFN-free treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN-free treatment
Trial: 26192385
Drug: Family-based behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family-based behavioral treatment (FBT) for obesity
Trial: 16496603
Drug: Non-diabetics after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-diabetics after administration of atropine (K-A)
Trial: 11932840
Drug: Group analysis
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group analysis of evaluations (treatment questions)
Trial: 10096582
Drug: Antiretroviral triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiretroviral triple combination therapy (after 1996)
Trial: 10096582
Drug: Antiretroviral triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiretroviral triple combination therapy (before 1996)
Trial: 8562300
Drug: Nefazodone hydrochloride
RxNorm normalized name: Nefazodone Hydrochloride
DrugBank: Nefazodone (DB01149)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nefazodone hydrochloride 200 mg twice daily for 6 days
Trial: 8562300
Drug: Cimetidine 300
RxNorm normalized name: cimetidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 300 mg four times daily for 6 days
Trial: 8562300
Drug: Nefazodone hydrochloride
RxNorm normalized name: Nefazodone Hydrochloride
DrugBank: Nefazodone (DB01149)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nefazodone hydrochloride 200 mg twice daily + Cimetidine 300 mg four times daily for 6 days
Trial: 2147630
Drug: 4 injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 injections regimen (basal-prandial with short-acting insulin before meals and isophane (NPH) insulin at bedtime)
Trial: 2147630
Drug: 5 injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 injections regimen (4 injections plus a second injection of isophane (NPH) insulin before breakfast)
Trial: 2147630
Drug: 4 injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 injections regimen
Trial: 2147630
Drug: 5 injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 injections regimen
Trial: 2147630
Drug: 4 injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 injections regimen and 5 injections regimen
Trial: 28289894
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy (gallium‐aluminum‐arsenide diode laser, 20 mW, applied in five doses)
Trial: 22116961
Drug: TIMA protocol
RxNorm normalized name: Olay Professional Acne Protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TIMA protocol treatment by TIMA-trained psychiatrists over a 12-week period
Trial: 22116961
Drug: TIMA protocol
RxNorm normalized name: Olay Professional Acne Protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TIMA protocol treatment
Trial: 21342376
Drug: Degarelix 80
RxNorm normalized name: degarelix 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Degarelix 80 mg monthly maintenance dose
Trial: 18538469
Drug: Degarelix 160
RxNorm normalized name: Degarelix
DrugBank: Degarelix (DB06699)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Degarelix 160 mg monthly maintenance dose
Trial: 21342376
Drug: Leuprolide 7.5
RxNorm normalized name: leuprolide 7.5 mg/month intramuscular kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leuprolide 7.5 mg monthly
Trial: 15654489
Drug: Bethanecol chloride
RxNorm normalized name: Bethanechol Chloride
DrugBank: Bethanechol (DB01019)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bethanecol chloride tablets (20 mg, as needed)
Trial: 9577354
Drug: Total Parenteral
RxNorm normalized name: TPN - total parenteral nutrition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total Parenteral Nutrition (TPN) for 7 days
Trial: 7604754
Drug: Quinine sulphate
RxNorm normalized name: Quinine sulphate
DrugBank: Quinine (DB00468)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Quinine sulphate capsule
Trial: 7604754
Drug: Quinine dihydrochloride
RxNorm normalized name: quinine dihydrochloride
DrugBank: Quinine (DB00468)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Quinine dihydrochloride plain tablet
Trial: 7604754
Drug: Quinine sulphate
RxNorm normalized name: Quinine sulphate
DrugBank: Quinine (DB00468)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Quinine sulphate sugar coated tablet
Trial: 7604754
Drug: Quinine hydrochloride
RxNorm normalized name: quinine hydrochloride
DrugBank: Quinine (DB00468)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Quinine hydrochloride (IV infusion)
Trial: 3075630
Drug: Pheniramine maleate
RxNorm normalized name: Pheniramine Maleate
DrugBank: Pheniramine (DB01620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pheniramine maleate (supplement) for the first 3 months
Trial: 3075630
Drug: Clofazimine and
RxNorm normalized name: Clofazimine
DrugBank: Clofazimine (DB00845)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clofazimine and dapsone (control) for 12 months without supplement
Trial: 19025407
Drug: 830-nm diode
RxNorm normalized name: NM-004
DrugBank: NM-004 (DB18066)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 830-nm diode laser treatment (10 Hz, 50% duty cycle, 60 mW, 9.7 J/cm²) for 2 weeks, 10-min sessions, 5 days a week
Trial: 19025407
Drug: Placebo (sham
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (sham laser treatment)
Trial: 19025407
Drug: 830-nm diode
RxNorm normalized name: NM-004
DrugBank: NM-004 (DB18066)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 830-nm diode laser treatment
Trial: 11015032
Drug: Zolpidem 8.03
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolpidem 8.03 mg
Trial: 11015032
Drug: Zolpidem 16.06
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolpidem 16.06 mg
Trial: 9445577
Drug: Dipotassium clorazepate
RxNorm normalized name: Dipotassium clorazepate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipotassium clorazepate 10 mg
Trial: 9445577
Drug: Dipotassium clorazepate
RxNorm normalized name: Dipotassium clorazepate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipotassium clorazepate 20 mg
Trial: 30169405
Drug: Neostigmine 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neostigmine 20 μg/kg and atropine 10 μg/kg
Trial: 18166839
Drug: Gemcitabine 1000
RxNorm normalized name: gemcitabine 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine 1000 mg/m2 on days 1 and 8 plus cisplatin 80 mg/m2 on day 1 (GC)
Trial: 18166839
Drug: Gemcitabine 1000
RxNorm normalized name: gemcitabine 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine 1000 mg/m2 on days 1 and 8 plus paclitaxel 200 mg/m2 on day 1 (GP)
Trial: 18166839
Drug: Gemcitabine 1000
RxNorm normalized name: gemcitabine 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine 1000 mg/m2 on days 1 and 8 plus carboplatin area under the curve 5.5 on day 1 (GCb)
Trial: 18166839
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy with gemcitabine (all regimens)
Trial: 15560162
Drug: Viagra (individually
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Viagra (individually adjusted dose for 6 months)
Trial: 15560162
Drug: Sialis (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sialis (20 mg for 6 months)
Trial: 15560162
Drug: Impase (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Impase (1 tablet every other day sublingually for 6 months)
Trial: 15560162
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of PDE‐5 inhibitors (Viagra, Sialis) and Impase
Trial: 8477555
Drug: Oral racemic
RxNorm normalized name: EPINEPHRINE,RACEMIC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral racemic ibuprofen (400 mg)
Trial: 8477555
Drug: Intravenous racemic
RxNorm normalized name: EPINEPHRINE,RACEMIC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous racemic ibuprofen (60-minute infusion)
Trial: 22854639
Drug: Cholecalciferol supplementation
RxNorm normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholecalciferol supplementation (75 µg or 3,000 IU per day)
Trial: 20231324
Drug: Sertraline plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline plus Naltrexone (200 mg/day + 100 mg/day)
Trial: 7969211
Drug: Naltrexone (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone (100 mg/day)
Trial: 15767536
Drug: Nandrolone decanoate
RxNorm normalized name: Nandrolone Decanoate
DrugBank: Nandrolone decanoate (DB08804)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nandrolone decanoate (100 mg) every other week by intramuscular injection
Trial: 15767536
Drug: Placebo (equivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (equivalent volume) every other week by intramuscular injection
Trial: 22210925
Drug: Orlistat (lipase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orlistat (lipase inhibitor)
Trial: 11729638
Drug: Alpha-glucosidase inhibitors
RxNorm normalized name: alpha glucosidase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha-glucosidase inhibitors (inhibitors of carbohydrate absorption)
Trial: 9041328
Drug: Treatment groups
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment groups in mean plasma RNA level
Trial: 7523914
Drug: Chronic exposure
RxNorm normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chronic exposure to arsenic via drinking water (412 micrograms/l)
Trial: 7523914
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (drinking water with arsenic average levels of 37.2 micrograms/l)
Trial: 3452274
Drug: Caffeine (230
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (230 mg)